Effect of Intravenous L-Carnitine in Chinese Patients with Chronic Heart Failure
Zhi-Cheng Jing,Bing-Xiang Wu,Jian-Jiang Peng,Li,Lei Pan,Shui-Ping Zhao,Dong-Ye Li,Zai-Xin Yu,Jian-Bin Gong,Qing-Yan Zhao,Jia-Ning Cao,Guo-Tai Sheng,Jue Li,Benjamin Xiaoyi Li,Su Jiang,Chaofan Liang,Erika Salvi,Valentina Carubelli
DOI: https://doi.org/10.1093/eurheartj/suw008
2016-01-01
European Heart Journal Supplements
Abstract:Chronic heart failure (CHF) may be associated with an energy deficit in cardiac muscle. As levo-carnitine (LC) is involved in the production of myocardial energy, it is hypothesized that LC supplementation may ameliorate CHF symptoms. This multicentre, randomized, double-blind, and placebo-controlled study included 265 patients with CHF. Patients were randomized to receive either LC or placebo, twice a day. Endpoints were measured after 7 days of treatment. Primary endpoint was a reduction of at least one NYHA class. Secondary endpoints were changes in 6-min walk distance (6-MWD) compared with baseline, either alone or in combination with NYHA class decrease, left ventricular ejection fraction, and NT-proBNP level, together with adverse events. The primary endpoint was reached in 60.9% of patients treated with LC, compared with only 44.7% of the placebo group ( P = 0.012). Among the secondary endpoints, 6-MWD, alone or in combination with NYHA class, improved significantly in the LC group compared with placebo ( P = 0.0497 and P = 0.003, respectively). l-Carnitine was well tolerated. The lowest baseline values of plasma-free carnitine were observed in patients with NYHA classes III and IV where the effect of LC supplementation was greatest ( P = 0.002). Treatment with LC significantly improved CHF symptoms in Chinese patients, probably by correcting a status of carnitine insufficiency.